Helix, a San Mateo CA-based population genomics and COVID-19 testing company, raised $50M in Series C funding.
The round was led by Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic and Temasek.
The company intends to use the funds to accelerate the organization’s population genomics platform across health systems, life sciences companies, and to continue COVID-19 testing and viral surveillance efforts.
Led by James Lu, MD, PhD, co-founder and CEO, Helix operates a CLIA-certified and-CAP-accredited sequencing laboratory, which powers both its Exome+® and COVID-19 viral sequencing efforts. Since its founding in 2015, the company has empowered hundreds of thousands of individuals to improve their lives through their DNA including through large-scale population health initiatives including Renown Health’s Healthy Nevada Project and Mayo Clinic’s Tapestry program.
Helix uses its proprietary Exome+® assay to sequence approximately 20,000 protein-coding genes and 300,000 informative non-coding regions, creating a genomic profile.